RedHill Biopharma Ltd. Announces Issuance of New U.S. Patent and Provides Update on RHB-104 for Treatment of Crohn's Disease

TEL-AVIV, Israel, Jan. 7, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill Biopharma"), an emerging Israeli biopharmaceutical company focusing primarily on the development and acquisition of late clinical-stage, patent-protected, new formulations and combinations of existing drugs, reported today the issuance of a new U.S. patent and that a multi-site initiation process is underway in the U.S., Canada and Israel for a first multi-center, randomized, double-blind, placebo-controlled, parallel group initial Phase III study (the "MAP US Study") to assess the efficacy and safety of fixed-dose combination RHB-104 in subjects with moderately to severely active Crohn's disease. The MAP US Study will be conducted under an Investigational New Drug (IND) application amended in August 2012 and recruitment is planned to commence in the second quarter of 2013.